Cite Filings / KROS / 0000902664-25-004410
Feed Companies Filings Check
Sign in
SCHEDULE 13D/A

Beneficial Ownership Report

Keros Therapeutics, Inc. · Filed 2025-10-15 · Acc 0000902664-25-004410

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

Around this filing

  • 2025-10-17 4 10% owner sold 4,787,331 shares at $17.75 ($84,975,125)
  • 2025-10-16 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-10-15 SC TO-C Written Communication Relating to an Issuer
  • 2025-10-15 8-K Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · Other events
  • 2025-10-15 4 10% owner sold 5,389,264 shares at $17.75 ($95,659,436)
  • 2025-10-15 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-08-21 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)
Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…